a public good project by the
Synthesis
Company
of California

© 2026

Parameswaran Nair | doi.page

0 works0 citations0 h-index

Parameswaran Nair

University of British Columbia(CA)St. Joseph’s Healthcare Hamilton(CA)

Publications by Year

Research Areas

Asthma and respiratory diseases, Respiratory and Cough-Related Research, Eosinophilic Esophagitis, Chronic Obstructive Pulmonary Disease (COPD) Research, IL-33, ST2, and ILC Pathways

Most-Cited Works

→ Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia(2009)1,350 cited
→ Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial(2016)1,348 cited
→ Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma(2018)1,122 cited
→ Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma(2017)1,012 cited
→ Reslizumab for Poorly Controlled, Eosinophilic Asthma: A Randomized, Placebo-controlled Study(2011)717 cited
→ Omalizumab for asthma in adults and children(2014)655 cited

→ Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia(2015)

449 cited

→ Role of Biologics in Asthma(2018)421 cited

→ Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma(2020)385 cited

→ Revisiting Type 2‐high and Type 2‐low airway inflammation in asthma: current knowledge and therapeutic implications(2016)365 cited